The case for investing in healthcare innovation
Healthcare is entering a period of profound change driven by necessity.
Rapid population aging, the rising burden of chronic diseases and an evolving landscape of biological threats are arguably placing unprecedented pressure on health systems.1,2
At the same time, decades of genomics research have unlocked new treatments across the healthcare spectrum – from oncology and neurology to the treatment of rare disorders.3 AI is reshaping drug discovery,4 robotics is transforming surgery,5 and digital healthcare is helping to enable earlier intervention.6 These are not isolated developments; they are converging to redefine the boundaries of medicine and creating the potential for care that can be more effective, personalized, affordable and resilient.
This convergence is opening a broad opportunity set for investors across the private markets’ spectrum: from venture capital backing frontier science, to growth equity scaling platforms, to buyouts integrating and institutionalizing mature businesses.
In this paper we explore how a balanced allocation across these stages can help investors to capture both near term adoption and long term transformation.
As healthcare increasingly intersects with digital, genomic and AI innovation, we believe disciplined portfolio construction and manager selection will be important to harnessing these trends and translating healthcare innovation into more attractive, resilient investment outcomes.
